U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949799) titled 'A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION' on Nov. 15.
Brief Summary: This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function
Study Start Date: Dec. 17
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: FXS6837 capsule
Mild hepatic impairment, FXS6837 125mg orally once.
Recruitment Stat...